Update on Anti-angiogenesis Therapy in Colorectal Cancer

Federico Nasroulah, Atsushi Ohtsu, Takayuki Yoshino, Naoto Yoshizuka, Kentaro Yamazaki, Ling Gao, Masahiro Gotoh, Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. Anticancer Research. ,vol. 35, pp. 4003- 4007 ,(2015)

Josep Tabernero, Heinz-Josef Lenz, Salvatore Siena, Alberto Sobrero, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Takayuki Yoshino, Richard M Goldberg, Daniel J Sargent, Andrea Wagner, Dirk Laurent, Michael Teufel, Michael Jeffers, Axel Grothey, Eric Van Cutsem, None, Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial The Lancet Oncology. ,vol. 16, pp. 937- 948 ,(2015) , 10.1016/S1470-2045(15)00138-2

Axel Grothey, E. Dawn Flick, Allen L. Cohn, Tanios S. Bekaii-Saab, Johanna C. Bendell, Mark Kozloff, Nancy Roach, Yong Mun, Susan Fish, Herbert I. Hurwitz, Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiology and Drug Safety. ,vol. 23, pp. 726- 734 ,(2014) , 10.1002/PDS.3633

Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864

Ros Wade, Ana Duarte, Mark Simmonds, Rocio Rodriguez-Lopez, Steven Duffy, Nerys Woolacott, Eldon Spackman, The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. PharmacoEconomics. ,vol. 33, pp. 457- 466 ,(2015) , 10.1007/S40273-015-0257-Z

Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108

A. Lange, A. Prenzler, M. Frank, M. Kirstein, A. Vogel, J.M. von der Schulenburg, A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. European Journal of Cancer. ,vol. 50, pp. 40- 49 ,(2014) , 10.1016/J.EJCA.2013.08.008

J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, E. Ioffe, T. Huang, C. Radziejewski, K. Bailey, J. P. Fandl, T. Daly, S. J. Wiegand, G. D. Yancopoulos, J. S. Rudge, VEGF-Trap: A VEGF blocker with potent antitumor effects Proceedings of the National Academy of Sciences of the United States of America. ,vol. 99, pp. 11393- 11398 ,(2002) , 10.1073/PNAS.172398299

Klaus Mross, Martin Büchert, Annette Frost, Michael Medinger, Peter Stopfer, Matus Studeny, Rolf Kaiser, Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis BMC Cancer. ,vol. 14, pp. 510- 510 ,(2014) , 10.1186/1471-2407-14-510

Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter, None, The biology of VEGF and its receptors. Nature Medicine. ,vol. 9, pp. 669- 676 ,(2003) , 10.1038/NM0603-669